During the past decade, Retina Associates of Cleveland conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 1 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Retina Associates of Cleveland" #1 sponsor was "Apellis Pharmaceuticals, Inc." with 2 trials, followed by "Genentech, Inc." with 2 trials sponsored, "Aerpio Therapeutics" with 1 trials sponsored, "National Eye Institute (NEI)" with 1 trials sponsored and "Pfizer" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Retina Associates of Cleveland" #1 collaborator was "National Center for Complementary and Integrative Health (NCCIH)" with 1 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator and "Office of Dietary Supplements (ODS)" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Retina Associates of Cleveland" are "Geographic Atrophy" (3 trials), "Macular Degeneration, Age-Related" (2 trials), "Age-related Macular Degeneration" (1 trials), "Cataract" (1 trials) and "Geographic Atrophy Secondary to Age-related Macular Degeneration" (1 trials). Many other conditions were trialed in "Retina Associates of Cleveland" in a lesser frequency.

Most popular intervention types in "Retina Associates of Cleveland" are "Drug" (7 trials), "Dietary Supplement" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Galegenimab" (2 trials), "Placebo" (2 trials), "AKB-9778" (1 trials), "APL-2" (1 trials) and "DHA/EPA" (1 trials). Other intervention names were less common.

The vast majority of trials in "Retina Associates of Cleveland" are 7 trials for "All" genders.

Currently, there are NaN active trials in "Retina Associates of Cleveland". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Retina Associates of Cleveland, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Retina Associates of Cleveland, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".